SCHEMBL2012022

SCHEMBL2012022

CC(C(N)=O)n1ccc2cc(Br)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
NTSR1 P30989 1/20 0.43
MCL1 Q07820 1/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 1/20 0.40
FABP4 P15090 2/20 0.39
FABP3 P05413 1/20 0.37
FABP2 P12104 1/20 0.37
FABP5 Q01469 1/20 0.37
ROCK1 Q13464 1/20 0.37
KMT2A Q03164 1/20 0.35
EPHX1 P07099 1/20 0.35
KRAS P01116 2/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
HTR7 P34969 1/20 0.34
HSP90AA1 P07900 1/20 0.34
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619844 0.86 NTSR1 (0.50) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL16627458 0.86 NTSR1 (0.50) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL22798848 0.86 NTSR1 (0.50) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL2006730 0.83 HTR2A (0.48) HTR2AHTR2CSLC6A2SLC6A4FABP4
SCHEMBL16627490 0.82 NTSR1 (0.44) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL16627486 0.82 NTSR1 (0.44) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL2007680 0.82 HTR2A (0.49) HTR2AHTR2CSLC6A2SLC6A4EPHX1
SCHEMBL16627489 0.80 FPR2 (0.45) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL15712255 0.79 HTR2A (0.54) HTR2AHTR2CNTSR1MCL1SLC6A2
SCHEMBL30861517 0.79 HTR2A (0.54) HTR2AHTR2CNTSR1MCL1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP claimed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
CN-1768036-A Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2006-05-03 CN claimed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
CN-100364973-C Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2008-01-30 CN disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
CN-1768036-A Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2006-05-03 CN disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 HTR2A 159/4885HTR2C 445/4885NTSR1 3172/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 HTR2A 159/4885HTR2C 445/4885NTSR1 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.